Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mahmoud Al Masry

Pain Medicine Andover, MA Medical Doctor

NPI 1851694889 CMS profile 1291494

138 Haverhill St, Andover, MA 01810

Open in the dashboard

General payments

$4,139

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mahmoud Al Masry of Andover, MA is reported in the CMS Open Payments database as having received $4,139 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,462 11
2024 General $260 6
2023 General $1,435 17
2022 General $814 27
2021 General $56 3
2020 General $65 2
2019 General $47 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mahmoud Al Masry
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mahmoud Al Masry were reported at $1,462. Among 95 Pain Medicine profiles paid that year, the median was $405 and the middle half received between $116 and $1,740.

Show as a table
Year Mahmoud Al Masry Pain Medicine median Middle half National median
2019 $47 $298 $103–$1,153 $163
2020 $65 $188 $57–$916 $114
2021 $56 $365 $109–$1,150 $132
2022 $814 $498 $104–$1,575 $149
2023 $1,435 $334 $108–$1,267 $160
2024 $260 $544 $144–$1,302 $164
2025 $1,462 $405 $116–$1,740 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,299 9 payments
  2. SPR Therapeutics, Inc $790 9 payments
  3. Medtronic, Inc. $706 14 payments
  4. HydroCision, Inc. $500 1 payment
  5. AbbVie, Inc. $239 12 payments
  6. Nevro Corp. $125 2 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $83 5 payments
  8. Curonix LLC $83 2 payments
  9. AstraZeneca Pharmaceuticals LP $74 4 payments
  10. Lundbeck LLC $48 2 payments
  11. Other $193 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,635 63 payments
  2. Travel and Lodging $1,004 5 payments
  3. Consulting Fee $500 1 payment
Products named General payments · program years 2019–2025
  1. PROCLAIM $1,027 5 payments
  2. SPRINT PNS System $790 9 payments
  3. INTELLIS ADAPTIVESTIM $679 13 payments
  4. TENJET $500 1 payment
  5. ETERNA $147 1 payment
  6. UBRELVY $143 7 payments
  7. Senza $125 2 payments
  8. NURTEC ODT $83 5 payments
  9. StimQ Receiver Stimulator Kit Channel A US w/Receiver $83 2 payments
  10. StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver $83 2 payments
  11. Other $847 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,076

Median for Neurology: 833

Drug cost

$118,139

Median for Neurology: $202,670

Branded share of claims

27.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 21 $32,170
Buprenorphine Generic 77 $15,825
Oxycontin Oxycodone Hcl Brand 31 $13,022
Belbuca Buprenorphine Hcl Brand 14 $10,364
Lidocaine Generic 85 $8,099
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 268 $6,699
Xtampza Er Oxycodone Myristate Brand 21 $6,305
Gabapentin Generic 294 $4,090
Celecoxib Generic 68 $3,246
Oxycodone Hcl Generic 251 $3,196

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$84,088

Medicare's payments for the services billed

Medicare patients

463

Average age 72

Services billed

1,135

253 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 43%
Depression 41%
Ischemic heart disease 37%
Chronic kidney disease 31%
COPD 28%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record